Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial

This RCT (n=350) found the addition of docetaxel to radiation therapy and androgen deprivation therapy did not improve overall survival in this setting; a benefit was suggested in those with PSA < 4 ng/mL but further study is needed to clarify.

Journal of Clinical Oncology